Novo Nordisk AS (WBO:NNO2) Future 3-5Y Total Revenue Growth Rate: N/A (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:NNO2 Novo Nordisk AS WBO:NNO2
77 GF Score
Price €40.09
GF Value €93.91
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Future 3-5Y Total Revenue Growth Rate?

Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Novo Nordisk AS's Future 3-5Y Total Revenue Growth Rate is N/A.

Novo Nordisk AS  (WBO:NNO2) Future 3-5Y Total Revenue Growth Rate Explanation

Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Novo Nordisk AS Future 3-5Y Total Revenue Growth Rate Related Terms

WBO:NNO2 vs LLY, JNJ, ABBV: Future 3-5Y Total Revenue Growth Rate Comparison

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Nordisk AS Future 3-5Y Total Revenue Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Future 3-5Y Total Revenue Growth Rate falls into.


WBO:NNO2
77GF Score
Novo Nordisk AS WBO:NNO2
Future 3-5Y Total Revenue Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novo Nordisk AS (WBO:NNO2) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of €40.09 is trading 57.3% below its estimated GF Value™ of €93.91. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for WBO:NNO2:

  • Future 3-5Y Total Revenue Growth Rate: N/A
  • GF Value™: €93.91 vs. price of €40.09 (57.3% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the WBO:NNO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
77GF Score

Get the complete analysis for WBO:NNO2

Future 3-5Y Total Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€40.09
Price
€93.91
GF Value